Compare Neurocrine Biosciences Inc (NBIX) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Star Bulk Carriers Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Star Bulk Carriers Corp trades at $29.8 (market cap $3.54B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.1× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Star Bulk Carriers Corp for 24 Days on average.
| NBIX | SBLK | |
|---|---|---|
Market Cap | $14.36B | $3.54B |
Volume | 1,237,180 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $185.50 | $32.49 |
52-Week Low | $123.10 | $16.79 |
Typical Hold Time | 23 Days | 24 Days |
Enterprise Value | $14.37B | $4.22B |
Dividend Yield | — | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Star Bulk Carriers (SBLK) trades at $29.75, up 0.2% today, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals, with Q2 2026 EPS of $1.21 beating estimates by 27% and a 45% year-over-year revenue surge. A $0.90 dividend for H2 2026 reflects robust free cash flow generation. Analyst consensus is strongly positive, with 14 buys out of 24 ratings, supported by recent insider buying activity.
The outlook for SBLK remains favorable due to consistent earnings beats, attractive valuation multiples, and management's commitment to returning capital. Key risks include shipping rate volatility and broader economic sensitivity. The stock presents a compelling opportunity for value and income investors, though exposure to cyclical industry trends warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
